Salim Laghouati

1.9k total citations · 1 hit paper
18 papers, 864 citations indexed

About

Salim Laghouati is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pharmacology. According to data from OpenAlex, Salim Laghouati has authored 18 papers receiving a total of 864 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 3 papers in Pharmacology. Recurrent topics in Salim Laghouati's work include Cancer Immunotherapy and Biomarkers (14 papers), Colorectal Cancer Treatments and Studies (4 papers) and CAR-T cell therapy research (3 papers). Salim Laghouati is often cited by papers focused on Cancer Immunotherapy and Biomarkers (14 papers), Colorectal Cancer Treatments and Studies (4 papers) and CAR-T cell therapy research (3 papers). Salim Laghouati collaborates with scholars based in France, Australia and United Kingdom. Salim Laghouati's co-authors include Aurélien Marabelle, Stéphane Champiat, Jean‐Marie Michot, Olivier Lambotte, Caroline Robert, Christine Mateus, Audrey Coilly, Bruno Roche, Barbara Papouin and Eléonora De Martin and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Gastroenterology.

In The Last Decade

Salim Laghouati

16 papers receiving 860 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors

2018 376 citations Eléonora De Martin, Jean‐Marie Michot et al. Journal of Hepatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Salim Laghouati France	8	710	162	161	158	116	18	864
Xiaoxiang Zhou China	9	514 0.7×	176 1.1×	104 0.6×	188 1.2×	46 0.4×	20	766
Aya Nakaya Japan	13	290 0.4×	131 0.8×	61 0.4×	98 0.6×	39 0.3×	54	601
Maya Gambarin‐Gelwan United States	10	271 0.4×	127 0.8×	268 1.7×	52 0.3×	176 1.5×	21	623
You‐Jian He China	14	508 0.7×	204 1.3×	151 0.9×	67 0.4×	159 1.4×	30	807
Atsushi Takeshita Japan	13	279 0.4×	140 0.9×	174 1.1×	34 0.2×	184 1.6×	40	580
Yuichiro Umemoto Japan	7	408 0.6×	131 0.8×	121 0.8×	114 0.7×	155 1.3×	7	594
Lígia Traldi Macedo Brazil	12	298 0.4×	174 1.1×	42 0.3×	40 0.3×	41 0.4×	29	499
Ketki Tendulkar United States	13	345 0.5×	265 1.6×	76 0.5×	48 0.3×	17 0.1×	22	645
Nicole A. Carreau United States	9	159 0.2×	55 0.3×	52 0.3×	73 0.5×	60 0.5×	12	677
Jeffrey Patton United States	11	203 0.3×	202 1.2×	59 0.4×	50 0.3×	32 0.3×	28	518

Countries citing papers authored by Salim Laghouati

Since Specialization

Citations

This map shows the geographic impact of Salim Laghouati's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Salim Laghouati with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Salim Laghouati more than expected).

Fields of papers citing papers by Salim Laghouati

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Salim Laghouati. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Salim Laghouati. The network helps show where Salim Laghouati may publish in the future.

Co-authorship network of co-authors of Salim Laghouati

This figure shows the co-authorship network connecting the top 25 collaborators of Salim Laghouati. A scholar is included among the top collaborators of Salim Laghouati based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Salim Laghouati. Salim Laghouati is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Berlanga, Pablo, Dan Chaltiel, Cyril Lervat, et al.. (2025). Phase Ib study of the combination of regorafenib with conventional chemotherapy in patients with newly diagnosed multi-metastatic Ewing sarcoma: The Rego-Inter-Ewing-1 study.. Journal of Clinical Oncology. 43(16_suppl). 10008–10008.

Rassy, Elie, Salim Laghouati, Thomas Petit, et al.. (2023). 156TiP Impact of neoadjuvant immunotherapy in early stage breast cancer before standard therapy (BIS-Program). ESMO Open. 8(1). 101495–101495. 1 indexed citations

Kfoury, Maria, Anne-Laure Voisin, Stéphane Champiat, et al.. (2022). Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias. Cancer Treatment Reviews. 110. 102452–102452. 35 indexed citations

Antoun, S., Émilie Lanoy, Samy Ammari, et al.. (2022). Protective effect of obesity on survival in cancers treated with immunotherapy vanishes when controlling for type of cancer, weight loss and reduced skeletal muscle. European Journal of Cancer. 178. 49–59. 23 indexed citations

Berlanga, Pablo, Nadège Corradini, Stéphane Ducassou, et al.. (2022). Securing access to innovative anticancer therapies for children, adolescents, and young adults outside clinical trials: The SACHA study of the French Society of Pediatric Oncology (SFCE).. Journal of Clinical Oncology. 40(16_suppl). 10006–10006. 7 indexed citations

Laparra, Ariane, François‐Xavier Danlos, Stéphane Champiat, et al.. (2021). The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry. European Journal of Cancer. 158. 217–224. 58 indexed citations

Baldini, Capucine, Andreea Varga, Séverine Mouraud, et al.. (2021). 1732MO Pembrolizumab and nintedanib for patients with advanced mesothelioma. Annals of Oncology. 32. S1198–S1198.

Laparra, Ariane, Maria Kfoury, Stéphane Champiat, et al.. (2021). Multiple immune-related toxicities in cancer patients treated with anti-programmed cell death protein 1 immunotherapies: a new surrogate marker for clinical trials?. Annals of Oncology. 32(7). 936–937. 5 indexed citations

Danlos, François‐Xavier, Capucine Baldini, Matthieu Texier, et al.. (2021). 378 Efficacy, safety and ancillary analyses of pembrolizumab in combination with nintedanib for the treatment of patients with relapsed advanced mesothelioma. SHILAP Revista de lepidopterología. A409–A409. 1 indexed citations

10.

Baldini, Capucine, P. Martin Romano, Anne-Laure Voisin, et al.. (2020). Impact of aging on immune-related adverse events generated by anti–programmed death (ligand)PD-(L)1 therapies. European Journal of Cancer. 129. 71–79. 63 indexed citations

11.

Ducassou, Stéphane, Helder Fernandes, Hélène Savel, et al.. (2020). Prospective Evaluation of the First Option, Second-Line Therapy in Childhood Chronic Immune Thrombocytopenia: Splenectomy or Immunomodulation. The Journal of Pediatrics. 231. 223–230. 1 indexed citations

12.

Baldini, Capucine, Patricia Martín-Romano, Anne-Laure Voisin, et al.. (2018). Incidence of immune related adverse events in patients 70 years old treated with anti-PD-(L)1 therapy. Annals of Oncology. 29. viii428–viii429. 4 indexed citations

13.

Martin, Eléonora De, Jean‐Marie Michot, Barbara Papouin, et al.. (2018). Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. Journal of Hepatology. 68(6). 1181–1190. 376 indexed citations breakdown →

14.

Kfoury, Maria, Anne-Laure Voisin, Stéphane Champiat, et al.. (2018). Association between immune-related adverse events and efficacy in patients treated with anti-PD-(L)1. Annals of Oncology. 29. viii405–viii405. 7 indexed citations

15.

Collins, Michael, Jean‐Marie Michot, Charlotte Mussini, et al.. (2017). Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies. Annals of Oncology. 28(11). 2860–2865. 124 indexed citations

16.

Collins, Michael, Jean‐Marie Michot, François‐Xavier Danlos, et al.. (2017). Gastrointestinal Immune Related Adverse Events Associated with Programmed-Death 1 Blockade. Gastroenterology. 152(5). S194–S194. 2 indexed citations

17.

Burel, S. Le, Stéphane Champiat, Christine Mateus, et al.. (2017). Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis. European Journal of Cancer. 82. 34–44. 148 indexed citations

18.

Michot, Jean‐Marie, Stéphane Champiat, Charlotte Mussini, et al.. (2017). P315 Gastrointestinal immune related adverse events associated with programmed-Death 1 blockade. Journal of Crohn s and Colitis. 11(suppl_1). S237–S237. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact